Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo

Trial Profile

A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2018

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ExFOS
  • Most Recent Events

    • 22 Apr 2018 Results (country subanalysis) assessing post teriparatide treatment patterns and effectiveness in standard clinical practise in Greek patients presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 22 Apr 2018 Results (n=735) of pooled analysis (subanalysis) of Greek patients from Efos and Exfos studies assessing non-vertebral, clinical vertebral and clinical fracture rates presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 08 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top